<DOC>
	<DOCNO>NCT00126321</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy cladribine , high-dose cytarabine idarubicin treatment patient relapse acute myeloid leukemia .</brief_summary>
	<brief_title>Cladribine , Cytarabine Idarubicin Patients With Relapsed Acute Myelocytic Leukemia ( AML )</brief_title>
	<detailed_description>Considerable progress make induction therapy acute myeloid leukemia ( AML ) ; however , current therapeutic result still unsatisfactory relapsed disease . The purine nucleoside analogue cladribine ( 2-chlorodeoxyadenosine , 2-CdA ) show safe active agent acute myeloid leukemia . Synergistic interaction cladribine cytarabine demonstrate preclinical clinical study . The current multicenter phase II study initiate evaluate efficacy toxicity cladribine , high-dose cytarabine , idarubicin treatment patient relapse AML . Adult patient age group enrol trial , elderly patient treat less dose-intensive regimen .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>Patients relapse AML remission duration least 6 month first complete remission ( CR ) least 3 month second ( high ) CR Age &gt; = 18 year Life expectancy least three month ( without consideration AML complication ) Eastern Cooperative Oncology Group ( ECOG ) 02 ( without consideration AML complication ) Written informed consent Prior therapy AML cladribine Severe , uncontrolled infection time inclusion ( enrollment possible control infection ) Cardiac insufficiency grade III IV New York Heart Association ( NYHA ) Severe renal insufficiency clearance &lt; 30 ml/min ( due AML ) Severe hepatic insufficiency bilirubin &gt; 3 mg/dl AST &gt; 200 U/l ( due AML ) Other severe organ impairment grade III IV World Health Organization ( WHO ) ( due AML , opinion investigator , may interfere procedure study ) HIV infection Intolerance study drug Pregnant breastfeed woman Any malignant disease probably affect course AML</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>AML , relapse</keyword>
	<keyword>cladribine</keyword>
	<keyword>chemotherapy</keyword>
</DOC>